Spots Global Cancer Trial Database for An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Official Title: An Open-Label, Randomized, Multicenter, Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Study ID: NCT02211222
Conditions
Interventions
Study Description
Brief Summary: This Expanded Access Program (EAP) consists of a Prerandomization Phase and a Randomization Phase. Only subjects with radioiodine-refractory DTC who fulfill the eligibility criteria will be treated. These subjects will be treated until progression of disease or unacceptable toxicity.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, La Jolla, California, United States
, Stanford, California, United States
, Torrance, California, United States
, Washington, District of Columbia, United States
, Chicago, Illinois, United States
, Boston, Massachusetts, United States
, Lansing, Michigan, United States
, Lebanon, New Hampshire, United States
, Neptune, New Jersey, United States
, Cleveland, Ohio, United States
, Portland, Oregon, United States
, Philadelphia, Pennsylvania, United States
, Houston, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
